Double maintains 3 strategies that include BMRN - BioMarin Pharmaceutical, Inc.
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| IQV | 46.68% | $28.16B | -27.38% | 0.00% |
| ITOS | 46.18% | $393.84M | -36.32% | 0.00% |
| TMO | 45.78% | $164.16B | -20.66% | 0.38% |
| AAPL | 45.33% | $3.15T | -8.41% | 0.48% |
| OBDC | 44.00% | $7.49B | -5.45% | 10.06% |
| MTD | 43.93% | $25.44B | -9.95% | 0.00% |
| AMGN | 43.78% | $158.77B | -10.75% | 3.14% |
| ARCC | 43.75% | $15.07B | - | 8.43% |
| BIIB | 43.61% | $19.67B | -41.66% | 0.00% |
| SLRC | 43.57% | - | - | 10.05% |
| IONS | 43.43% | $6.64B | -13.06% | 0.00% |
| NOVT | 42.88% | $4.74B | -23.38% | 0.00% |
| DD | 42.81% | $31.59B | -6.66% | 2.11% |
| RVTY | 42.48% | $11.96B | -7.32% | 0.28% |
| EFX | 42.48% | $32.13B | +0.27% | 0.65% |
| QRVO | 42.16% | $8.19B | -28.15% | 0.00% |
| BRKR | 42.13% | $6.64B | -32.37% | 0.46% |
| LYB | 41.60% | $20.75B | -32.10% | 8.41% |
| A | 41.49% | $35.02B | -6.77% | 0.81% |
| KRYS | 41.36% | $4.28B | -27.06% | 0.00% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| TDUP | -11.69% | $837.19M | +300.00% | 0.00% |
| AQB | -10.42% | $3.00M | -57.88% | 0.00% |
| HUSA | -9.06% | $23.23M | +4.02% | 0.00% |
| K | -7.17% | $27.56B | +40.50% | 2.87% |
| VHC | -5.85% | $69.94M | +179.66% | 0.00% |
| STG | -5.55% | $47.31M | +7.56% | 0.00% |
| UUU | -4.95% | $7.70M | +126.53% | 0.00% |
| MKTX | -4.61% | $8.10B | +1.50% | 1.39% |
| DFDV | -4.24% | $401.69M | +2,774.82% | 0.00% |
| PSQH | -4.22% | $105.20M | -41.22% | 0.00% |
| PHYS | -3.71% | - | - | 0.00% |
| SYPR | -2.87% | $47.57M | +11.29% | 0.00% |
| NUVL | -2.75% | $5.81B | +2.90% | 0.00% |
| UFI | -2.71% | $88.68M | -16.15% | 0.00% |
| GFI | -1.51% | $21.61B | +50.75% | 2.30% |
| AIFU | -1.41% | $17.04M | +83.91% | 0.00% |
| RLMD | -1.23% | $20.25M | -84.98% | 0.00% |
| VSA | -1.22% | $10.37M | +7.96% | 0.00% |
| MVO | -1.08% | $68.54M | -39.92% | 21.06% |
| RLX | -0.95% | $2.07B | +25.41% | 0.44% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BBH | 58.41% | $345.62M | 0.35% |
| IBB | 57.19% | $5.59B | 0.45% |
| PBE | 56.92% | $233.59M | 0.58% |
| FBT | 55.94% | $1.05B | 0.54% |
| VHT | 53.99% | $15.49B | 0.09% |
| XBI | 53.92% | $5.19B | 0.35% |
| FHLC | 53.63% | $2.46B | 0.084% |
| IYH | 53.16% | $2.76B | 0.39% |
| IXJ | 52.26% | $3.80B | 0.41% |
| XLV | 51.97% | $34.28B | 0.09% |
| RSPH | 51.89% | $728.37M | 0.4% |
| GNOM | 50.68% | $45.27M | 0.5% |
| MOAT | 50.68% | $12.98B | 0.47% |
| PINK | 50.51% | $132.39M | 0.5% |
| XPH | 50.01% | $155.51M | 0.35% |
| PPH | 49.48% | $544.00M | 0.36% |
| FXH | 49.16% | $891.10M | 0.62% |
| IHE | 49.14% | $562.06M | 0.39% |
| JEPI | 48.75% | $41.11B | 0.35% |
| BALT | 48.55% | $1.56B | 0.69% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| CARY | -0.15% | $347.36M | 0.8% |
| TOTL | -0.29% | $3.81B | 0.55% |
| FLMI | -0.31% | $745.34M | 0.3% |
| SPTL | 0.37% | $11.26B | 0.03% |
| DBE | -0.40% | $53.74M | 0.77% |
| IBTP | -0.49% | $143.68M | 0.07% |
| JBND | 0.50% | $2.36B | 0.25% |
| SCHQ | 0.54% | $784.68M | 0.03% |
| CANE | -0.55% | $11.17M | 0.29% |
| SUB | 0.58% | $9.98B | 0.07% |
| GOVI | 0.62% | $939.24M | 0.15% |
| BNDW | 0.72% | $1.29B | 0.05% |
| STIP | 0.74% | $12.73B | 0.03% |
| VGLT | 0.79% | $9.70B | 0.04% |
| USL | 0.83% | $43.14M | 0.85% |
| SHYD | 0.84% | $332.11M | 0.35% |
| UNG | 0.89% | $416.42M | 1.06% |
| BNO | 0.90% | $108.34M | 1% |
| BSV | -0.91% | $38.00B | 0.03% |
| FMHI | 0.91% | $748.97M | 0.7% |
Current Value
$58.061 Year Return
Current Value
$58.061 Year Return
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| TAIL | -43.41% | $94.90M | 0.59% |
| VIXY | -41.22% | $200.94M | 0.85% |
| VIXM | -39.71% | $22.99M | 0.85% |
| IVOL | -18.52% | $341.06M | 1.02% |
| FTSD | -18.12% | $233.24M | 0.25% |
| XONE | -16.95% | $629.16M | 0.03% |
| FXY | -16.83% | $798.58M | 0.4% |
| ULST | -15.65% | $592.71M | 0.2% |
| GBIL | -14.87% | $6.37B | 0.12% |
| BTAL | -14.78% | $310.24M | 1.43% |
| SPTS | -14.34% | $5.78B | 0.03% |
| TPMN | -13.06% | $30.86M | 0.65% |
| CLIP | -12.98% | $1.51B | 0.07% |
| FXE | -11.38% | $592.85M | 0.4% |
| TBLL | -11.12% | $2.12B | 0.08% |
| IBTG | -10.49% | $1.93B | 0.07% |
| UTWO | -10.34% | $376.64M | 0.15% |
| BWX | -10.29% | $1.53B | 0.35% |
| VGSH | -10.28% | $22.70B | 0.03% |
| SHV | -10.20% | $20.75B | 0.15% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CBOE | 0.13% | $24.61B | +38.65% | 1.07% |
| PRPO | -0.17% | $23.55M | +232.09% | 0.00% |
| EDSA | 0.25% | $14.68M | -50.94% | 0.00% |
| VSTA | -0.30% | $324.82M | +33.88% | 0.00% |
| CPSH | 0.51% | $36.46M | +48.52% | 0.00% |
| SATS | -0.55% | $8.87B | +57.45% | 0.00% |
| ZCMD | 0.76% | $29.04M | -9.45% | 0.00% |
| DRD | 0.82% | $1.17B | +41.04% | 2.03% |
| EVGO | 0.90% | $462.88M | -13.75% | 0.00% |
| GALT | 0.94% | $158.86M | +12.05% | 0.00% |
| RLX | -0.95% | $2.07B | +25.41% | 0.44% |
| CLLS | 0.96% | $114.63M | -23.92% | 0.00% |
| ASND | 0.97% | $10.56B | +26.71% | 0.00% |
| MVO | -1.08% | $68.54M | -39.92% | 21.06% |
| VSA | -1.22% | $10.37M | +7.96% | 0.00% |
| RLMD | -1.23% | $20.25M | -84.98% | 0.00% |
| AIFU | -1.41% | $17.04M | +83.91% | 0.00% |
| TH | 1.42% | $795.91M | -10.70% | 0.00% |
| GFI | -1.51% | $21.61B | +50.75% | 2.30% |
| SAVA | 1.73% | $102.90M | -81.49% | 0.00% |
Yahoo
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the 11 best debt-free stocks to invest in right now. On July 2, Morgan Stanley analyst Sean Laaman initiated coverage on BioMarin with a Buy rating and a $97 price target, citing a favorable outlook despite ongoing competitive concerns. Laaman’s optimism centers on Voxzogo, BioMarin’s therapy for achondroplasia, a […]
Yahoo
BioMarin (BMRN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
SeekingAlpha
The ClearBridge Sustainability Leaders Strategy outperformed its Russell 3000 Index benchmark in the second quarter. Read more here.
Yahoo
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the 10 Best Growth Stocks to Buy With Huge Upside Potential. On July 1, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced the finalization of its acquisition of Inozyme Pharma, Inc. The deal is valued at $270 million, and BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has paid $4.00 per share in cash for all […]
Yahoo
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said today that it completed the previously announced agreement to acquire Inozyme Pharma, Inc. (Nasdaq: INZY) for $4.00 per share in an all-cash transaction worth approximately $270 million. The acquisition will strengthen BioMarin's enzyme therapies portfolio, adding a late-stage enzyme replacement therapy, INZ-701. The medicine is currently being developed for the treatment of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) Deficiency, a
Finnhub
BioMarin Pharmaceutical Inc. dropped from Russell 1000 Value-Defensive Index...
